Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT06191718
Other study ID # CP-004
Secondary ID
Status Active, not recruiting
Phase N/A
First received
Last updated
Start date March 1, 2023
Est. completion date December 1, 2024

Study information

Verified date December 2023
Source Foldax, Inc
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to conduct a clinical investigation of the Foldax Tria Mitral Valve to collect evidence on the device's safety and performance.


Description:

The Foldax Tria Mitral Heart Valve is indicated as a replacement for diseased, damaged, or malfunctioning native mitral heart valve via open heart surgery. The study is a single open are label non-randomized multi- center clinical trial. Up to 10 sites in the country of India will enroll up to 70 patients. The first two patients at each site, will be considered roll-in patients accounting for training. Up to 50 patients will be considered part of the treatment phase. These patients will follow the study schedule for 1 year after implantation.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 70
Est. completion date December 1, 2024
Est. primary completion date December 1, 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Is 18 years or older - Is a candidate for mitral valve replacement with cardiopulmonary bypass - Is a candidate for mitral valve replacement due to severe mitral valve disease - No contraindication for anticoagulation treatment - Willing and able to comply with protocol requirements Exclusion Criteria: - Requires valve replacement other than mitral - Prior mitral valve surgery for valve replacement or valve repair (this does NOT include percutaneous interventions i.e. Mitraclip, chordal replacement) - Required concomitant cardiovascular procedures except for CABG and/or COX-MAZE if approved by the screening committee - Requires emergency surgery - Requires other planned surgery within 12 months of valve replacement - Active endocarditis or active myocarditis - Exhibits left ventricular ejection fraction </= 20% as validated by diagnostic procedure prior to planned valve surgery - Acute preoperative neurological deficit defined as neurological deficit < 3 months prior to enrollment - Life expectancy of less than 12 months - Enrolled in another investigational device or drug study (enrolled patients may not enroll in other studies) - Myocardial infarction, or severe cardiac adverse event which has not returned to baseline for at least 30-days prior to enrollment - Aortic aneurysm or other medical condition that creates a higher than usual risk of surgical complications - Renal insufficiency as determined by creatinine (S-CR) level as >/= 2.0 mg/dl or end stage renal disease requiring chronic dialysis at screening visit - Results for the following blood tests are not within normal limits: D-Dimer, Basic Metabolic Panel Liver enzymes, Coagulation Profile - platelets, APTT, INR, Fibrinogen, C-reactive protein (HSCRP) and ESR, and Troponin levels - Hematological disorders, patients must not have a hematocrit of <30%, hemoglobin <10 g/dL, platelet count of <100,000 cells/µL, or WBC <4,000 cells/µL; coagulation profile must not be outside of normal limits - Patients who are pregnant or expect to become pregnant in the 12 months following implantation, or are lactating - Any other condition that, in the judgment of the investigator and screening committee, makes the patient a poor candidate for the procedure, the study or compliance with the protocol (includes vulnerable patient population, mental illness, addictive disease, extensive travel away from the research center, COVID-19 related concerns) - Patients who have withdrawn after implantation may not re-enter - Intraoperatively it is determined that the patient anatomy is not compatible with the device.

Study Design


Intervention

Device:
Mitral Valve Replacement
Foldax Mitral Valve Replacement

Locations

Country Name City State
India Epic Hospital Ahmedabad Gujarat
India GCS Medical College Ahmedabad Gujarat
India Fortis Hospital Delhi
India Indo-US Hospital Hyderabad Telangana
India SMS Hospital Jaipur Rajasthan
India NRS Medical College and Hospital Kolkata West Bengal
India Hinduja Hospital and Medical Research Centre Mumbai Maharashtra
India KEM Hospital Mumbai Maharashtra
India Six Sigma Nashik Maharashtra
India B.J. Medical College Pune Maharashtra

Sponsors (1)

Lead Sponsor Collaborator
Foldax, Inc

Country where clinical trial is conducted

India, 

Outcome

Type Measure Description Time frame Safety issue
Primary Primary Safety Endpoints Serious Adverse Event (SAE) rates for any valve related events. Results are compared descriptively to event rates reported in the literature. 12 months after last patient enrollment
Primary Primary Effectiveness Endpoint- Change in Hemodynamic Performance Hemodynamic performance parameters are mmHG mean gradient, peak gradient, and derived Effective Orifice Area (EOA). Success is defined as clinically significant improvement in hemodynamic performance (mean/peak gradient and Effective Orifice Area (EOA)) at one year based on literature reports for surgical mitral valve replacement. 12 months after last patient enrollment
Primary Clinical Effectiveness Endpoint- Change in New York Heart Association Assessment Clinically significant improvement (one grade) in the New York Heart Association (NYHA) functional classification status at 365 days compared to baseline. a. Class I - No symptoms and no limitations in ordinary physical activity, e.g. shortness of breath when walking, climbing stairs etc. b. Class II - Mild symptoms (mild shortness of breath and/or angina) and slight limitation during ordinary activity. c. Class III - Marked limitation in activity due to symptoms, even during less-than-ordinary activity, e.g. walking short distances (20-100m). Comfortable only at rest. d. Class IV - Severe limitations. Experiences symptoms even while at rest. Mostly bedbound patients. 12 months after last patient enrollment
Secondary Number of Participants with Stroke Assessment of patient experiencing a stroke (ex; ischemic stroke, intracerebral hemorrhage, subarachnoid hemorrhage, or other) verified by imaging and or physical exam 1 year following patient enrollment
Secondary Number of Participants with Structural Valve Deterioration (SVD) Assessment of patient experiencing SVD as verified by imaging, procedure, or physical exam 1 year following patient enrollment
Secondary Number of Participants with Transient Ischemic Attack Assessment of patient having a TIA as verified by imaging and or physical exam 1 year following patient enrollment
Secondary ICU Duration of Stay Length of stay in the ICU post valve implantation defined as arrival time/date in hours and minutes to transfer to floor time/date in hours and minutes. 30 Days post patient enrollment
Secondary Ventilation Time Ventilation time in hours defined as arrival time/date in recovery in hours and minutes to date and time extubated in hours and minutes 30 Days post patient enrollment
Secondary Post Procedure length of stay Post procedure length of stay defined as the time/date documented for arrival in the recovery unit to date/ time of discharge in hours and minutes. 30 days post patient enrollment
Secondary Kansas City Cardiomyopathy Questionnaire Change in QOL as measured by the KCCQ. Scores are measured from 0-100, in hich higher scores reflect better health status. 12 months post patient enrollment
Secondary Six Minute Walk Test Change in patients activity tolerance as documented by a 6 Minute Walk Test assessed by distance traveled after 6 minutes 12 months post patient enrollment
See also
  Status Clinical Trial Phase
Completed NCT03278574 - Flexible Band vs Rigid Ring for Degenerative Mitral Valve Disease N/A
Suspended NCT04960280 - A Study to Evaluate a Computerized Stethoscope Called ©Voqx to Diagnose Heart Disease N/A
Recruiting NCT05021614 - Valveclip® Transcatheter Mitral Valve Repair Study N/A
Not yet recruiting NCT06465745 - AltaValve Pivotal Trial N/A
Not yet recruiting NCT06167213 - ALLIANCE Mitral: Safety and Effectiveness of SAPIEN X4 Transcatheter Heart Valve - Mitral N/A
Withdrawn NCT05040451 - Carillon Mitral Contour System for Treatment of Exercise Induced Functional Mitral Regurgitation
Withdrawn NCT03714412 - Feasibility Study of Patients With Severe MR Treated With the Cardiovalve TMVR System N/A
Recruiting NCT02592889 - (MitraClip in Non-Responders to Cardiac Resynchronization Therapy) Phase 4
Completed NCT02355418 - The Role of Myocardial Fibrosis in Degenerative Mitral Regurgitation
Completed NCT01841554 - Cardioband With Transfemoral Delivery System N/A
Not yet recruiting NCT01431222 - Abrogation of Mitral Regurgitation Using the MitraClip System in High-Risk Patients Unsuitable for Surgery Phase 4
Not yet recruiting NCT03870516 - Left Chamber Function in Mitral Regurgitation and Predicting Outcome After Replacement and Targeting for Early Surgery N/A
Active, not recruiting NCT03230747 - SAPIEN M3 EFS: Early Feasibility Study of the Edwards SAPIEN M3 System for the Treatment of Mitral Regurgitation N/A
Enrolling by invitation NCT04031274 - Transcatheter Treatment for Combined Aortic and Mitral Valve Disease. The Aortic+Mitral TRAnsCatheter (AMTRAC) Valve Registry
Completed NCT05850026 - Mitral Regurgitation in Hypertrophic Obstructive Cardiomyopathy: Fix it in a Simple, Effective and Durable Way!
Completed NCT05836480 - Immediate Suboptimal Result of Mitral Valve Repair: Late Implications in a Matched Cohort Study
Completed NCT05836532 - Long Term Results of Surgical and Percutaneous Double Orefices Mitral Repair in Patient With p2 Prolapse Causing Degenerative Mitral Regurgitation
Recruiting NCT03975998 - Dutch-AMR: Early Mitral Valve Repair Versus Watchful Waiting in Asymptomatic Patients With Severe Mitral Regurgitation
Completed NCT01162083 - Identifying an Ideal Cardiopulmonary Exercise Test Parameter N/A
Suspended NCT00787293 - Study of Safety and Efficacy of the Percutaneous Reduction of Mitral Valve Regurgitation in Heart Failure Patients Phase 2